Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Lifecore Biomedical Inc.(LFCR)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for LFCR
09/25/2026: LFCR (1-star) is currently NOT-A-BUY. Pass it for now.
Lifecore Biomedical is a specialized contract development and manufacturing organization (CDMO) focused on complex sterile injectable products. Following a strategic transformation from a diversified holding company to a pure-play medical provider, the company offers a focused exposure to the drug delivery market. Its primary strengths reside in its technical expertise in sterile fill-finish and proprietary hyaluronic acid technology. However, the company faces execution risks related to operational scaling, high customer concentration, and intense competition from larger, global contract manufacturers. Investors should monitor progress in securing high-value manufacturing contracts and maintaining regulatory compliance, as these are critical factors for long-term growth in this niche, capital-intensive sector.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers growth potential through CDMO service expansion but carries operational risks. |
| Momentum investor | Mixed fit | Momentum depends on the stock demonstrating consistent positive signals following strategic milestones. |
| Value investor | Weak fit | Valuation is difficult to assess given the recent restructuring and transition phase. |
| Dividend investor | Weak fit | The company does not pay a dividend and is reinvesting cash into operations. |
| Low-risk investor | Weak fit | The company's status as a smaller player in a highly regulated industry involves significant business risk. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is susceptible to fluctuations based on operational news and sectoral sentiment. |
| Valuation risk | Medium / high | Valuation is contingent on meeting future revenue targets for its CDMO pipeline. |
| Competition risk | High | Large CDMOs like TMO and CTLT have significant scale advantages. |
| Business quality | Medium | The business has high barriers to entry but is early in its pure-play execution. |
| Dividend income | Low / none | Income investors should not look here for yield. |
| Execution risk | High | The company must deliver on complex regulatory and manufacturing milestones. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -51.13% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 158.98M USD | Price to earnings Ratio - | 1Y Target Price 6.75 |
Price to earnings Ratio - | 1Y Target Price 6.75 | ||
Volume (30-day avg) 139.1K shares | Beta 1.08 | 52 Weeks Range 3.63 - 8.98 | Updated Date 09/26/2026 |
52 Weeks Range 3.63 - 8.98 | Updated Date 09/26/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.27 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| CDMO Services | Sterile fill-finish, clinical development, and commercial manufacturing. | The company earns revenue by manufacturing injectable drugs for pharmaceutical partners. |
| Hyaluronan Products | Sodium hyaluronate production for eye care and orthopedic applications. | Revenue is generated from selling a key raw ingredient used in medical treatments. |
Valuation
Trailing PE - | Forward PE 8.67 | Enterprise Value 307.79M | Price to Sales(TTM) 1.23 |
Enterprise Value 307.79M | Price to Sales(TTM) 1.23 | ||
Enterprise Value to Revenue 2.36 | Enterprise Value to EBITDA 8.11 | Shares Outstanding 37.85M | Shares Floating 19.33M |
Shares Outstanding 37.85M | Shares Floating 19.33M | ||
Percent Insiders 2.8 | Percent Institutions 77.3 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Lifecore Biomedical Inc.
Exchange NASDAQ | Headquarters Chaska, MN, United States | ||
IPO Launch date 1996-02-15 | President, CEO & Director Mr. Paul Josephs | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 382 | Website https://www.lifecore.com |
Full time employees 382 | Website https://www.lifecore.com | ||
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.